N@N

David Lebowitz Downgraded (BPMC) to Strong Sell and Decreased Target to $41 on, Jun 10th, 2022

^{Published on 2024-10-27 21:28:38 - WOPRAI, David Lebowitz}
 

David Lebowitz of Citigroup, Downgraded "Blueprint Medicines Corporation" (BPMC) to Strong Sell and Decreased Target from $68 to $41 on, Jun 10th, 2022.

David has made no other calls on BPMC in the last 4 months.

There are 5 other peers that have a rating on BPMC. Out of the 5 peers that are also analyzing BPMC, 2 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Christopher Raymond of "Piper Sandler" Maintained at Hold with Decreased Target to $65 on, Thursday, May 19th, 2022
• Andrew Berens of "SVB Leerink" Downgraded from Buy to Hold and Decreased Target to $82 on, Thursday, February 17th, 2022

These are the ratings of the 3 analyists that currently disagree with David

---

• Eun Yang of "Jefferies" Upgraded from Hold to Strong Buy and Decreased Target to $78 on, Wednesday, June 1st, 2022
• Bradley Canino of "Stifel" Maintained at Strong Buy with Increased Target to $105 on, Friday, March 4th, 2022
• Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $100 on, Thursday, February 17th, 2022

Contributing Sources

---